CNTB connectbiopharm.com: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Connect Biopharma Holdings Limited (CNTB)

Connect Biopharma prospects rely on the success of rademikibart trials against asthma. However, intense competition in the dermatology niche demands flawless drug safety, while business development depends on passing tests and the availability of capital. The long-term debt-to-equity ratio reflects a balance sheet recovery trend, with the metric reaching 0.01, allowing for an assessment of the company's financial stability.

CNTB - connectbiopharm.com Long-Term Debt to Equity over the range 07/04/2022 - 10/29/2026

Comprehensive metric breakdowns and analytics for Connect Biopharma Holdings (CNTB)

- price and consensus price forecast:
Quote Chart Connect Pharma|CNTB - Analyst Consensus Forecast
- market capitalization data:
Market Value Connect Biopharma Holdings Limited|CNTB - Enterprise Value
- book capitalization data:
Book Value per Share Connect Biopharma|CNTB - Company Book Value|Market Value to Book Value connectbiopharm.com|CNTB - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Connect Biopharma|CNTB - Long-Term Debt to Capital|Short-Term Debt to Capital Connect Pharma|CNTB - Company Total Debt|Debt to Net Assets Ratio Connect Biopharma Holdings Limited|CNTB - Company Long-Term Debts|Short-Term Debt Volume Connect Biopharma
Initial company analysis:CNTB, connectbiopharm.com
Core merchandise of Connect Biopharma Holdings

The stability of Connect Biopharma (CNTB) depends on the patent protection of unique molecules for skin therapy. This long-term debt-to-equity ratio compares the company's market value with obligations exceeding one year. An increase in this metric signals overleverage or a decline in capitalization. For a biotech firm, this is a critical marker of financial sustainability during clinical trials. A decrease in the indicator confirms a fair valuation and low default risks.

Direct competitors

Long-Term Liabilities to Equity argenx N.V.|BioNTech Group (BNTX) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Abivax S.A. (ABVX)|Long-Term Debt to Capital ADMA (ADMA Biologics)|protagonist-inc.com - Long-Term Debt to Capital|Long-Term Debt to Equity Immunovant (IMVT)|KNSA: Long-Term Debt to Capital Coefficient|GRFS (Grifols Group) - Long-Term Debt to Equity|Adaptive Biotechnologies Inc. (ADPT) - Long-Term Debt to Equity Ratio|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com (AUPH)|BioCryst Pharmaceuticals (BCRX) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Vera Therapeutics Inc (VERA)|Long-Term Debt to Capital DNTH|Pharvaris Pharma - Ratio of Long-Term Indebtedness to Capital|ABCL: Long-Term Debt to Equity|TRML: Long-Term Debt to Equity Ratio|PGEN (Precigen) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|NKTR (Nektar) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital UPB|Long-Term Debt to Equity Zenas Biopharma Inc ZBIO|Long-Term Debt to Capital Ratio immunome.com (IMNM)|GOSS: Long-Term Debt to Capital|Long-Term Liabilities to Capital KalVista Pharma KALV|SEPN: Long-Term Debt to Capital|PVLA: Long-Term Debt to Equity Ratio|Long-Term Debt to Equity SVRA|RIGL (rigel.com) - Long-Term Liabilities to Capital|Long-Term Debt to Equity AnaptysBio (ANAB)|Long-Term Debt to Capital Ratio ATXS|Long-Term Debt to Equity enGene Bio ENGN|Long-Term Debt to Capital Ratio rapt.com (RAPT)|JBIO: Long-Term Debt to Capital|Long-Term Liabilities to Capital aclaristx.com ACRS|KYTX: Long-Term Debt to Capital|Tiziana Life Sciences Ltd. (TLSA) - Long-Term Debt to Equity Ratio|CABA - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio Ventyx Biosciences, Inc|THTX - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient avalotx.com|Long-Term Debt to Capital Eledon Pharmaceuticals, Inc. (ELDN)|Long-Term Debt to Equity Agenus, Inc. (AGEN)|Long-Term Debt to Capital CLYM|zurabio.com - Ratio of Long-Term Indebtedness to Capital|ATYR (aTyr Pharma, Inc.) - Long-Term Debt to Equity|ADAG: Long-Term Liabilities to Capital|Long-Term Debt to Equity ikenaoncology.com (IMA)|Shattuck Labs (STTK) - Long-Term Liabilities to Equity|EQ - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Immunic Inc|Long-Term Debt to Capital ATRA|Long-Term Debt to Capital IFRX (inflarx.de)|Long-Term Debt to Equity X4 Pharmaceuticals, Inc.|Adicet Bio Inc. - Long-Term Debt to Capital Coefficient|CELU: Long-Term Debt to Equity|INMB - Long-Term Debt to Equity Ratio|BRNS: Long-Term Debt to Capital|kezarlifesciences.com (KZR) - Long-Term Debt to Capital|Long-Term Debt to Capital SABS|Long-Term Debt to Equity Ratio AKTX|Long-Term Debt to Equity Enlivex Therapeutics ENLV|Long-Term Debt to Capital Ratio q32bio.com QTTB|Long-Term Debt to Equity Ratio GeoVax Labs, Inc. (GOVX)|Long-Term Loans to Capital Ratio edesabiotech.com EDSA|IBIO - Long-Term Debt to Capital|CARM: Long-Term Debt to Equity|Long-Term Debt to Equity XTL Biopharmaceuticals, Ltd. (XTLB)|Bolt Biotherapeutics, Inc. (BOLT) - Long-Term Liabilities to Equity|HCWB - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Aptevo|Long-Term Debt to Capital AIM|Long-Term Debt to Capital ADTX (aditxt.com)|Long-Term Debt to Equity GRI Bio Corp|XORTX Corp - Long-Term Debt to Capital Coefficient|HIND: Long-Term Debt to Equity|REVB - Long-Term Debt to Equity Ratio|INDP: Long-Term Debt to Capital|Long-Term Debt to Capital Scinai Immunotherapeutics Ltd|CALI - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Affimed Therapeutics|ALLK (Allakos Inc.) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital HOOK (hookipapharma.com)|IGM Biosciences - Long-Term Debt to Equity|iTeos Therapeutics Inc - Long-Term Debt to Equity Ratio|OCEA: Long-Term Debt to Equity|TC BioPharm Ltd (TCBP) - Long-Term Debt to Equity Ratio|THRD: Long-Term Debt to Equity Ratio